Daishi Tian
Clinical trials sponsored by Daishi Tian, explained in plain language.
-
Experimental CAR-T therapy targets Hard-to-Treat muscle disease
Disease control Recruiting nowThis early-phase study tests a new treatment called GC012F for people with a severe muscle inflammation disease (idiopathic inflammatory myopathy) that hasn't responded to standard therapies. About 12 adults will receive an infusion of their own modified immune cells (CAR-T cells…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 26, 2026 02:14 UTC
-
Experimental CAR t therapy aims to tame multiple sclerosis
Disease control Recruiting nowThis early study is testing a new treatment called GC012F, which uses a patient's own immune cells (CAR T cells) to target multiple sclerosis. The main goal is to see if it is safe and tolerable for people with MS. Only 9 participants will be enrolled, and they will be monitored …
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 26, 2026 02:11 UTC
-
Experimental injection targets Hard-to-Treat muscle weakness
Disease control Recruiting nowThis early study tests an injection called GC012F in 6 people with refractory generalized myasthenia gravis, a condition causing severe muscle weakness. The main goal is to check safety and see if the treatment helps. Researchers will monitor side effects and measure how the ther…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 22, 2026 13:54 UTC